Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term trial. Found 103 abstracts

no pagination
Zijoo R, Olszanski AJ, Weinberg DS. Biomarkers and stage II colorectal cancer therapy. Translational Cancer Research. 2016 Jun;5:S84-S86.   PMCID: Editorial
Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas(dagger). Annals of Oncology. 2013 Jan;24(1):257-63.   PMCID: not NIH funded
Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA. Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Oct;10(10):1211-9.   PMCID: not NIH funded
Benson A, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA. Anal Carcinoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Apr;10(4):449-54.   PMCID: not NIH funded
Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecologic Oncology. 2012 Sep;126(3):375-80.
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Dec;127(3):538-43.   PMCID: PMC3568489
Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer. 2012 Jan;48(1):85-93.   PMCID: Private funding
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study. Clinical Lymphoma Myeloma & Leukemia. 2012 Aug;12(4):238-43.   PMCID: *
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Annals of Oncology. 2012 May;23(5):1144-50.   PMCID: *
Hoppe RT, Advani RH, Ai WY, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H. Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 May;10(5):589-97.   PMCID: not NIH funded
Hossain M, Schirmer T, Richardson T, Chen LL, Buyyounouski MK, Ma CM. Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate. International Journal of Radiation Oncology Biology Physics. 2012 May;83(1):451-8.   PMCID: not NIH funded
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of Surgical Oncology. 2012 May;19(5):1508-16.   PMCID: not NIH funded
Keller LM, Buyyounouski MK, Sopka D, Ruth K, Klayton T, Pollack A, Watkins-Bruner D, Greenberg R, Price R, Horwitz EM. Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer. Urology. 2012 Aug;80(2):337-42.   PMCID: PMCID:PMC3461589[Available on 2013/8/1]
Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia & lymphoma. 2012 Feb;53(2):275-81.
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.   PMCID: PMC3494424
Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou XF, Danaee H, Schilder RJ. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecologic Oncology. 2012 Oct;127(1):63-9.   PMCID: Not NIH Funded
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Sep;10(9):1081-7.   PMCID: Not NIH Funded
Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, Shapiro CL, Stearns V, Christos P, Espinoza-Delgado I, Bhalla K, Sparano JA. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Research and Treatment. 2012 Apr;132(3):1063-72.   PMCID: *
Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Jan;124(1):53-8.   PMCID: *
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term trial

trial radiation-therapy cell lung-cancer cancer survival chemotherapy combination cells bevacizumab metastatic breast-cancer carcinoma colorectal-cancer 1990 lkman j-journal of the national cancer institute-v82-p4 pharmacokinetics randomized-trial growth risk receptors ag-013736 paclitaxel axitinib-docetaxel-capecitabine-solid tumours 1st-line therapy mice metastatic colorectal-cancer Prostatic neoplasms recommendations a kinase microsatellite instability prognostic indicators irradiation combination therapy primary cytoreductive surgery renal Ovarian cancer Aurora A kinase-MLN8237-Platinum-refractory-Platinum-resistant her-2 gemcitabine endorectal mr progression phase-iii Endometrial cancer Aflibercept-VEGF Trap-Toxicity-Fibroblast growth factor t-cell lymphoma interleukin-6 pancreatic-cancer phase-ii macroglobulinemia clinical-trial breast-cancer prognosis fdg-pet Dynamic contrast-enhanced Primary peritoneal cancer-magnetic resonance imaging-GOG igm stem-cell transplantation 1987 en ss-gynecologic oncology-v27-p368 HER2 circulating tumor cells-immunohistochemical subtypes-metastatic breast cancer-tumor markers Lymphadenopathy Interleukin-6 persistent guideline international index cancer patients Paclitaxel Metastatic breast cancer-Bevacizumab-Vorinostat-HDAC inhibitors pegylated liposomal doxorubicin failure lesions weekly bortezomib Ovarian cancer free survival vegf plus bevacizumab suberoylanilide hydroxamic acid surgical adjuvant breast positron-emission-tomography tumor-development Multiple myeloma quadrivalent vaccine involved-field 2nd international workshop system 10-deazaaminopterin cell mortality colon-cancer nocturnal penile tumescence lenalidomide women ixabepilone soft-tissue sarcomas 2 cycles Safety features dose-rate brachytherapy Siltuximab Prostate magnetic resonance spectroscopy Magnetic resonance spectroscopy-Gold marker seeds therapy men Prednisone college Mitoxantrone doxorubicin lymphadenectomy phase-2 consensus panel recommendations tumors localization endocrine therapy bevacizumab angiosarcoma-hemangioendotheliomas-soft tissue sarcoma node involvement sequential therapy immunoglobulin-m paclitaxel multicenter brachytherapy infection expression external-beam radiotherapy cyclophosphamide chemotherapy androgen deprivation markers radiotherapy follow-up disease heat-shock-protein-90 expert panel extramedullary docetaxel randomized high-dose chemoradiotherapy prostate fluorouracil peripheral-blood regimen abiraterone acetate Treatment efficacy kras human-papillomavirus end-points metastasis endothelial growth-factor intraepithelial neoplasia Efficacy Antifolate-Relapsed-Refractory peripheral T-cell lymphoma-Safety-Transformed mycosis fungoides impact FIGO staging preoperative chemotherapy pathological complete response rituximab dominant intraprostatic lesions impotence 2010 bono js-35 ann c eur soc med leucovorin bortezomib prednisone
Last updated on Wednesday, March 04, 2020